Entries |
Document | Title | Date |
20080227866 | Hydroxyphenylalkadiones and Their Use for Masking Bitter Taste and/or for Intensifying Sweet Taste | 09-18-2008 |
20080312333 | Agent for Preventing/Ameliorating Life Style-Related Diseases Containing Turmeric Essential Oil Component - The present invention has its object to provide an agent for preventing and/or ameliorating life style-related diseases which contains, as an active ingredient, a substance derived from a safe food material having a long history of being eaten as a food and which is capable of being utilized as functional foods such as health foods or functional health foods (specific health foods, functional nutritive foods). | 12-18-2008 |
20090149550 | WRINKLE REDUCTION AGENT, LIPOLYSIS ACCELERATOR, COMPOSITION FOR EXTERNAL USE ON SKIN, AND FOOD OR BEVERAGE COMPOSITION - An antiwrinkle agent, lipolysis promoter, external composition for skin, and food and beverage composition having for an active ingredient thereof a compound represented by general formula (1): | 06-11-2009 |
20090209651 | USE OF 3-(4-HYDROXY-3-METHOXYPHENYL)-1-(4-HYDROXYPHENYL) PROPANE-1-ONE FOR IMPROVED SKIN CONTOURING OR AGAINST CELLULITE - A cosmetic or dermatological preparation which is suitable for application to skin and comprises 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propane-1-one in a concentration which is effective for at least one of increasing skin moisture content, moisturizing skin, improving the surface structure of the skin, reducing cellulite, increasing the resilience and elasticity of skin, strengthening the connective tissue of skin, and reducing stretch marks on skin. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way. | 08-20-2009 |
20090221714 | Pharmaceutical Composition for Prevention and Treatment of Drug or Alcohol Addiction or Bipolar Disorder Using Sodium Phenylbutyrate - Provided is a pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder, comprising sodium phenylbutyrate (PBA). The pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder in accordance with the present invention provides effects capable of inhibiting increases in locomotor activity which is a behavioral indicator of drug or alcohol addiction or bipolar disorder, by controlling a level of a neurotransmitter via regulation of expression of a neurotransmitter transporter. | 09-03-2009 |
20100099775 | METHOD FOR AMELIORATING OF POST-ANESTHETIC RECOVERY - The invention describes use of injectable form of Idebenone to improve recovery after general anesthesia and of cognitive functions, suppress disorientation and other signs of neuronal damage. | 04-22-2010 |
20100152301 | Treatment of Viral Infections - Treatment of cells or subjects (e.g., humans, animals) carrying or infected with a virus capable of causing an immunodeficiency disease by administration of one or more compounds that inhibit integrase. | 06-17-2010 |
20100160448 | COMPOSITIONS, METHODS OF USE AND PREPARATION OF 2,6-DIISOPROPYL PHENOL AND ANALOGS FOR ISCHEMIC INJURY - The present invention provides novel 2,6-diisopropyl phenol 2,6-diisopropyl phenol analogs and sterile, stable pharmaceutical compositions of 2,6-diisopropyl phenol 2,6-diisopropyl phenol and analogs thereof useful as an antioxidant in the treatment of ischemic injury including stroke and other cerebral injury. 2,6-diisopropyl phenol or its analogs are administered in a dosage effective to produce blood levels and brain levels of the drug that can prevent free radical damage associated with ischemic injury. | 06-24-2010 |
20100197801 | Volatile Distillate By-Product of Mint Oil That Promotes Absorption and/or Bioavailability of Compounds of Bio-Medical and Nutritional Interest - Disclosed is an adjuvant for improving the bioavailability of bioactive compositions. The adjuvant is prepared from a byproduct of mint flavor production. In vitro and in vivo testing confirms effectiveness. The adjuvant contains a mixture of compounds which is effective to improve the oral bioavailability of a bioactive composition normally having limited absorptivity, and it comprises a mixture of nonpolar compounds and compounds with some polar characteristics. In preferred form the nonpolar compounds comprise compounds selected from a group that includes terpene hydrocarbons and terpene derivatives and the compounds with some polar characteristics comprise compounds selected from a group that includes aldehydes, alcohols and ketones. The preferred compositions will have a ratio of nonpolar compounds and compounds with some polar characteristics is within the range of from 5:1 to 20:1. The adjuvants can enhance delivery of CoQ10 and other bioactive compositions, such as carotenoids (e.g., β-carotene), curcuminoids, lycopene, resveratrol, flavonoids and other phenolic compounds, organosulfur compounds, saponins, sterols, stanols, and mixtures of at least two of these, to the interior cellular environment, including organelles, such as the mitochondria. | 08-05-2010 |
20100222436 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS - Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. | 09-02-2010 |
20100286283 | MICROTUBULE-DISRUPTNG AGENT AND CANCER CELL PROLIFERATION INHIBITOR CONTAINING THE SAME - The present invention provides a novel microtubule-disrupting agent, and also provides a use of the microtubule-disrupting agent. A microtubule-disrupting agent containing an α,β-unsaturated carbonyl compound as an active ingredient is provided. Further, a cancer cell proliferation inhibitor containing the microtubule-disrupting agent is also provided. As the α,β-unsaturated carbonyl compound, 6-shogaol is preferably used. | 11-11-2010 |
20110136916 | 6-SHOGAOL FOR USING IN A METHOD FOR THE TREATMENT OF LEUKEMIA - The present invention relates to the field of natural drugs, particularly to 6-shogaol for using in a method for the treatment of leukemia. The present invention provides a method for treating leukemia by applying a therapeutically effective dose of 6-shogaolt and this therapeutic method can be used for treating leukemia in mammals including human being. | 06-09-2011 |
20110207828 | METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA - The present invention provides methods for the treatment, amelioration, or prevention of a symptom of neuronal damage associated with cerebral ischemia comprising administering compositions comprising a compound of Formula I. | 08-25-2011 |
20110213038 | CONTROL OF BED BUGS - Control of bed bugs by bringing the bed bugs into contact with a bed bug control formulation containing at least one of carvone, linalool, styralyl alcohol, dihydrocarvone, tetrahydrocarvone, and mixtures thereof and method for achieving such control. | 09-01-2011 |
20110263720 | SYNTHESIS OF ALPHA-TOCOPHEROLQUINONE DERIVATIVES, AND METHODS OF USING THE SAME - The present invention is directed to a method of synthesizing a compound of Formula I: | 10-27-2011 |
20120010297 | CURCUMINOIDS AND ITS METABOLITES FOR THE APPLICATION IN ALLERGIC OCULAR/NASAL CONDITIONS - A pharmaceutical composition for nasal administration comprising: a nanoemulsified curcumin component; a liquid medium for the curcumin component; and a pharmaceutically acceptable excipient. The curcumin component is a natural curcuminoid, a synthetic curcuminoid, a metabolite of a natural or synthetic curcuminoid, or a mixture thereof. The excipient is effective in increasing the bioavailability of the curcumin component. | 01-12-2012 |
20120322888 | ANTIWRINKLE AGENT, LIPOLYSIS PROMOTER, EXTERNAL COMPOSITION FOR SKIN AND FOOD AND BEVERAGE COMPOSITION - An antiwrinkle agent, lipolysis promoter, external composition for skin, and food and beverage composition having for an active ingredient thereof a compound represented by general formula (1): | 12-20-2012 |
20130023589 | MEDICATION FOR THERAPY OR PROPHYLAXIS OF ASTHMA - A medication for therapy or prophylaxis of asthma, comprises a ginger compound selected from a group of [6]-gingerol, [10]-gingerol, [6]-shogaol and [6]-gingerol; and an acceptable carrier or excipient, which can relieve the airway remodeling symptoms of asthma, particularly to phthalate induced airway remodeling, by suppressing the proliferation and migration of bronchial smooth muscle cells and reducing the instances of fatal asthma. | 01-24-2013 |
20130281543 | METHOD OF TREATING AIRWAY REMOLDING SYMPTOM - A method of treating airway remolding symptom caused by phthalate esters, by providing a medication comprising: a ginger compound selected from one of (a) [6]-shogaol, (b) [6]-shogaol and [10]-gingerol, (c) [6]-shogaol and [8]-gingerol, and (d) [6]-shogaol and [6]-gingerol, and an acceptable carrier or excipient, which can relieve, the airway remodeling symptoms of asthma, particularly to phthalate ester-induced airway remodeling, by suppressing the proliferation and migration of bronchial smooth muscle cells and reducing the instances of fatal asthma. | 10-24-2013 |
20140031431 | PEST-IMPERVIOUS PACKAGING MATERIAL AND PEST-CONTROL COMPOSITION - A composition-of-matter comprising a substance usable in producing packaging material and at least one compound selected from the group consisting of ar-turmerone, a sesquiterpene alcohol and a turmeric oleoresin solid residue. | 01-30-2014 |
20140039064 | USE OF GINGERONE OR DERIVATIVES THEREOF FOR REDUCING OR DELAYING THE SIGNS OF SKIN AGEING - Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing. The present invention relates to the cosmetic use of at least one compound of general formula (I): in which:—R | 02-06-2014 |
20140057991 | Cosmetic composition comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone - The invention relates to a composition comprising, in a physiologically acceptable aqueous medium, 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and a solvent with solubility parameters in the Hansen solubility space such that 4.5<δ, <30 and 15<δ | 02-27-2014 |
20140213660 | USE OF ((ETHOXY)HYDROXYPHENYL)ALKYL KETONE OR ETHOXYHYDROXYALKYLPHENOL COMPOUNDS FOR TREATING GREASY SKIN - The present invention relates to a cosmetic method for treating and/or preventing greasy skin or greasiness-prone skin and/or the associated cutaneous aesthetic defects, comprising the topical application to the skin of a composition comprising, in a cosmetically acceptable medium, at least one compound of formula (I): | 07-31-2014 |
20140243420 | ANTICONVULSANT ACTIVITY OF TURMERIC OIL AND BISABOLENE SESQUITERPENOIDS - The present invention relates to the anti-convulsant activity of turmeric oil and its volatile bisabolene sesquiterpenoids ar-turmerone, α-turmerone, β-turmerone (curlone) and α-atlantone, as an anticonvulsant agent for the treatment of epilepsy and/or as therapeutic agents for the treatment of disorders of the central nervous system, including tremor, pain, mood disorders (including depression, bipolar disorder, attention deficit-hyperactivity disorder, and schizophrenia), and neurodegenerative diseases. | 08-28-2014 |
20160136110 | Method for Treating a Neurodegenerative Event - A method of neuroprotection or treating or healing a wound, orifice, surgical site or a neurodegenerative event in an individual or animal via modulation of at least one neurotrophin by administering a therapeutically effective amount of at least one fatty acid amide hydrolase (FAAH) inhibitor or a physiologically acceptable salt thereof to the individual or animal. Administration of the at least one FAAH inhibitor may be via release from an article of manufacture that includes a support. | 05-19-2016 |
20170231883 | USE OF 4-(3-ETHOXY-4-HYDROXYPHENYL)ALKYLKETONE AS A SKIN-SOOTHING AGENT | 08-17-2017 |